

AD \_\_\_\_\_

Award Number DAMD17-96-1-6060

**TITLE:** Antagonistic Action of Hyaluronan Oligomers in Breast Cancer

**PRINCIPAL INVESTIGATOR:** Bryan P. Toole, Ph.D.  
Jeanine Ward

**CONTRACTING ORGANIZATION:** Tufts University  
Boston, Massachusetts 02111

**REPORT DATE:** September 1999

**TYPE OF REPORT:** Annual

**PREPARED FOR:** U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

**DISTRIBUTION STATEMENT:** Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20000907 145

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

|  |  |   |  |
|--|--|---|--|
| 1. AGENCY USE ONLY (Leave blank)   | 2. REPORT DATE   | 3. REPORT TYPE AND DATES COVERED                        |  |
|  | September 1999   | Annual (1 Sep 98 - 31 Aug 99)                           |  |
| 4. TITLE AND SUBTITLE<br>Antagonistic Action of Hyaluronan Oligomers in Breast Cancer  |  |   | 5. FUNDING NUMBERS<br>DAMD17-96-1-6060           |
| 6. AUTHOR(S)<br>Bryan P. Toole, Ph.D.<br>Jeanine Ward  |  |   |  |
| 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)<br>Tufts University<br>Boston, Massachusetts 02111<br><br>E-MAIL: btoole@infonet.tufts.edu , jward@infonet.tufts.edu  |  |   | 8. PERFORMING ORGANIZATION REPORT NUMBER         |
| 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)<br>U.S. Army Medical Research and Materiel Command<br>Fort Detrick, Maryland 21702-5012  |  |   | 10. SPONSORING / MONITORING AGENCY REPORT NUMBER |
| 11. SUPPLEMENTARY NOTES  |  |   |  |
| 12a. DISTRIBUTION / AVAILABILITY STATEMENT<br>Approved for public release; distribution unlimited  |  |   | 12b. DISTRIBUTION CODE                           |
| 13. ABSTRACT (Maximum 200 Words)<br><br>The objective of this project is to determine whether hyaluronan interactions are involved in growth and invasion of mammary carcinoma cells in ascites. Syngeneic mice were injected intraperitoneally with stable transfecants of TA3/St murine mammary carcinoma cells that overexpress soluble CD44, a hyaluronan-binding protein that would be expected to compete with endogenous hyaluronan-protein interactions. The behavior of these transfecants was compared with that of transfecants expressing mutated soluble CD44 that does not bind hyaluronan. Overexpression of soluble CD44, but not mutated soluble CD44, inhibited tumor cell growth in ascites as well as invasion of the peritoneal wall. When grown in vitro in soft agar, the soluble CD44 transfecants exhibited a dramatic reduction in colony formation compared to wild type, vector-transfected and mutant soluble CD44-transfected TA3/St cells. Thus, perturbation of hyaluronan interactions by soluble CD44 has a direct effect on the growth characteristics of these tumor cells, leading to inhibition of anchorage independent growth in vitro and ascites growth in vivo. |  |   |  |
| 14. SUBJECT TERMS<br>Breast Cancer, Murine Mammary Carcinoma<br>Hyaluronan, CD44, Invasion   |  |   | 15. NUMBER OF PAGES<br>8                         |
|  |  |   | 16. PRICE CODE                                   |
| 17. SECURITY CLASSIFICATION OF REPORT<br>Unclassified  | 18. SECURITY CLASSIFICATION OF THIS PAGE<br>Unclassified | 19. SECURITY CLASSIFICATION OF ABSTRACT<br>Unclassified | 20. LIMITATION OF ABSTRACT<br>Unlimited          |

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)  
Prescribed by ANSI Std. Z39-18  
298-102

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

N/A For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

N/A In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

N/A In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

  
PI - Signature      Date 4/30/99

## TABLE OF CONTENTS

|                         |        |
|-------------------------|--------|
| Front Cover -----       | Page 1 |
| Standard Form 298 ----- | Page 2 |
| Foreword -----          | Page 3 |
| Table of Contents ----- | Page 4 |
| Introduction -----      | Page 5 |
| Body -----              | Page 5 |
| Appendices -----        | Page 8 |

## (5) INTRODUCTION

The objective of this project is to determine whether hyaluronan interactions are involved in growth and invasion of mammary carcinoma cells in ascites. Hyaluronan accumulates in ascites during intraperitoneal proliferation of TA3/St murine mammary carcinoma cells and at sites of their invasion of the peritoneal wall. To determine whether hyaluronan is functionally involved in these events, mice were injected intraperitoneally with stable transfectants of TA3/St cells that overexpress soluble CD44, a hyaluronan-binding protein that would be expected to compete with endogenous hyaluronan-protein interactions. The behavior of these transfectants was compared with that of transfectants expressing mutated soluble CD44 that does not bind hyaluronan. We have reported previously that the soluble CD44 transfectants temporarily grew at a reduced rate within the peritoneal cavity, then went into G1 arrest and were subsequently cleared from the peritoneum. However, the transfectants overexpressing mutant soluble CD44 that does not bind hyaluronan exhibited similar ascites accumulation, growth rates and cell cycle profiles *in vivo* to wild type and vector-transfected TA3/St cells, all of which continued to grow until the tumors became fatal. The soluble CD44-transfected TA3/St cells also failed to attach to and form tumors in the peritoneal wall. These experiments suggest that perturbation of hyaluronan interactions by soluble CD44 alters the growth characteristics of the tumor cells, leading to inhibition of ascites growth and invasion *in vivo*. However, it was not clear whether overexpression of soluble CD44 has a direct effect on tumor cell behavior or whether its effect was an indirect consequence of another event *in vivo*. In the experiments reported here, we have begun to investigate whether inhibition of tumor growth is due to direct or indirect effects.

## (6) BODY

**Soluble CD44-Transfected TA3/St Mammary Carcinoma Cells Have Lost the Capacity for Anchorage Independent Growth *In Vitro*.** Since it was not clear from the *in vivo* results obtained previously whether overexpression of soluble CD44 has a direct effect on tumor cell growth or whether its effect was an indirect consequence of another event *in vivo*, we sought additional evidence to discriminate between these two possible explanations.

First, proliferation of the soluble CD44 transfectants and control cells was compared in monolayer culture in tissue culture wells. Each cell line grew at approximately the same rate over a five day period and all cell lines exhibited similar cell cycle profiles (Table 1). This result was in contrast to the differences observed previously between the growth of soluble CD44 transfectants in ascites vs that of controls in ascites, where the former were found to go into G1 arrest (Table 1).

We then examined anchorage independent growth of the various cell lines in soft agar. Soft agar assays were performed in 60 mm dishes containing 2 ml of 1.2% agarose diluted with 2x DME medium containing 20% fetal bovine serum (FBS) to yield a final agarose concentration of 0.6%. Cells were harvested from monolayer culture in log growth phase by trypsinization, washing and resuspension in DME medium containing 10% FBS for

counting. The cells were then suspended in 0.33% agarose in DME medium containing 10% FBS, with or without 0.5 mg/ml Geneticin, and plated at 5000 cells/ well on top of the 0.6% agarose base. After each agarose layer was allowed to solidify (10 min at 25°), three additional 1 ml volumes of 0.33% agarose were layered on top of the cells. Each cell line was plated in triplicate and grown at 37° for 28 days. Total numbers of colonies per well containing >30 cells or >200 cells per colony were counted separately using a microscope grid. The two classes of colony size were assessed by counting cells in numerous colonies under the microscope and correlating these numbers with colony size. The two classes could be distinguished readily since the great majority of colonies were found to contain between 30 and 100 cells; the large colonies (>200 cells) were very easily distinguished from the majority of colonies (30-100 cells) and there were virtually no colonies with <30 cells.

Dramatic differences in size and number of colonies formed between the soluble CD44 transfectants and control cells were observed (Table 2). The wild type, vector-transfected cells and mutant soluble CD44-transfected cells formed many times more colonies than the soluble CD44 transfectants, and the colonies formed by the control cells were much larger than those few colonies formed by the soluble CD44 transfectants (Table 2).

Thus we have shown that the soluble CD44 transfectants, but not the mutant soluble CD44 transfectant, have lost their ability to exhibit anchorage independent growth in soft agar, one of the most reliable indicators for the transformed state of cells. We conclude that endogenous hyaluronan produced by the tumor cells themselves directly serves an important function in anchorage independent growth, and that hyaluronan interactions at the cell surface are, at least under some circumstances, crucial to mammary cancer cell growth characteristics *in vitro* and *in vivo*.

**Table 1 Soluble CD44 transfectants of mammary carcinoma cells exhibit G1 arrest *in vivo* but not *in vitro***

| Cell type                             | % Cells in G0/G1 |                |
|---------------------------------------|------------------|----------------|
|                                       | In vitro         | In vivo        |
| <b>Controls:</b>                      |                  |                |
| Wild type TA3/St                      | 44.1 $\pm$ 0.5   | 30.0 $\pm$ 2.1 |
| Vector transfectant                   | 28.3 $\pm$ 1.5   | 38.2 $\pm$ 5.4 |
| Soluble CD44 v6-v10 R43A <sup>a</sup> | 33.3 $\pm$ 0.9   | 39.1 $\pm$ 4.8 |
| <b>Soluble CD44 Transfectants:</b>    |                  |                |
| Soluble CD44 v6-v10a                  | 44.7 $\pm$ 1.6   | 86.2 $\pm$ 1.0 |
| Soluble CD44 v6-v10b                  | 37.0 $\pm$ 2.1   | 76.4 $\pm$ 4.1 |
| Soluble CD44 v8-v10                   | 53.0 $\pm$ 1.2   | 74.3 $\pm$ 2.8 |

<sup>a</sup>The R43A clone expresses mutated soluble CD44 that does not bind hyaluronan

**Table 2 Soluble CD44 transfectants of mammary carcinoma cells fail to form colonies in soft agar**

| Cell type                             | Number of colonies <sup>a</sup> |            |
|---------------------------------------|---------------------------------|------------|
|                                       | >30 cells                       | >200 cells |
| <b>Controls:</b>                      |                                 |            |
| Wild type TA3/St                      | 205 $\pm$ 28                    | 30 $\pm$ 2 |
| Vector transfectant                   | 83 $\pm$ 21                     | 25 $\pm$ 9 |
| Soluble CD44 v6-v10 R43A <sup>b</sup> | 409 $\pm$ 11                    | 39 $\pm$ 5 |
| <b>Soluble CD44 Transfectants:</b>    |                                 |            |
| Soluble CD44 v6-v10a                  | 1 $\pm$ 0                       | 0 $\pm$ 0  |
| Soluble CD44 v6-v10b                  | 16 $\pm$ 4                      | 5 $\pm$ 1  |
| Soluble CD44 v8-v10                   | 8 $\pm$ 1                       | 0 $\pm$ 0  |

<sup>a</sup>Numbers represent means ( $\pm$ SD) of the total numbers of colonies with >30 or >200 cells per colony in triplicate wells.

<sup>b</sup>The R43A clone expresses mutated soluble CD44 that does not bind hyaluronan

**Completion of Ph.D. requirements by Rebecca Moore Peterson.** Rebecca Peterson has now completed all requirements for the Ph.D. in Cell, Molecular and Developmental Biology at Tufts University and has been awarded the Ph.D. She is currently employed as an Instructor in Biology at Penn State University.

**Transfer of award to Jeanine Ward.** This award has now been transferred to Ms Jeanine Ward. Ms Ward will continue the above work, utilizing additional approaches to determine the effect of hyaluronan on tumor cell growth and invasion.

## **(7) APPENDICES**

### **Key research accomplishments:**

- a. Demonstration that hyaluronan interactions are crucial to growth of murine mammary carcinoma cells in ascites
- b. Demonstration that hyaluronan interactions are crucial to invasion of murine mammary carcinoma cells from ascites into the peritoneal wall
- c. Demonstration that hyaluronan interactions are crucial to anchorage independent growth of murine mammary carcinoma cells in vitro

### **Outcomes:**

- a. Manuscript in preparation reporting above results
- b. Ph.D. in Cell, Molecular and Developmental Biology at Tufts University awarded to Rebecca Peterson
- c. Award of National Cancer Institute grant (RO1 CA82867) to pursue work based in part on results described above